Form 4: OnKure Therapeutics Director Isaac Manke Acquires 7,650 Stock Options

OnKure Therapeutics, Inc. Director Isaac Manke has acquired 7,650 stock options with an exercise price of $2.44, vesting by May 28, 2026, or the next annual meeting.

Summary

• Isaac Manke, a Director of OnKure Therapeutics, Inc. (OKUR), reported the acquisition of derivative securities on May 28, 2025.
• The transaction involved 7,650 stock options, granting the right to buy Class A Common Stock.
• The exercise price for these options is $2.44 per share.
• The options have an expiration date of May 27, 2035.
• The shares subject to the option will vest 100% on the earlier of May 28, 2026, or the day prior to the Issuer's next annual meeting of stockholders, contingent on Mr. Manke's continued service.
• Following this transaction, Mr. Manke beneficially owns 7,650 derivative securities directly.

Sentiment

Score: 7

Explanation: The acquisition of stock options by a director is generally a positive signal, indicating continued commitment and alignment of interests. It's a standard compensation practice and not indicative of negative sentiment.

Positives

• The acquisition of stock options by a director indicates continued alignment of interests with shareholders, as the options gain value only if the stock price increases.
• The vesting schedule encourages long-term commitment and continued service from the director.

Risks

• The vesting of the acquired options is contingent upon Mr. Manke continuing as a service provider through the applicable vesting date; unvested options would be forfeited if his service ceases.
• The value realized from these options is dependent on the future market price of OnKure Therapeutics, Inc. Class A Common Stock exceeding the exercise price of $2.44.

Future Outlook

The vesting schedule for the acquired stock options extends to May 28, 2026, or the date prior to the next annual meeting, indicating a future incentive for the director's continued service and alignment with long-term company performance.

Industry Context

Form 4 filings are routine disclosures for insider transactions. The grant of stock options is a common form of equity compensation for directors, aligning their interests with shareholders by incentivizing long-term stock price appreciation. This is standard practice across many industries, particularly in biotechnology where long development cycles necessitate long-term incentives.

Comparison to Industry Standards

• The grant of stock options to directors is a standard practice in corporate governance across various industries, including biotechnology.
• The exercise price of $2.44 is specific to OnKure Therapeutics and its current valuation, and its attractiveness depends on the company's future performance relative to this price.
• Vesting schedules, such as the one-year cliff or annual meeting-based vesting, are common mechanisms to ensure continued service and align director incentives with long-term shareholder value creation, comparable to practices at companies like Moderna (MRNA) or BioNTech (BNTX) for their non-executive directors.

Stakeholder Impact

• Shareholders: The grant of stock options to a director aligns their interests with shareholders, as the options gain value only if the stock price increases, potentially benefiting shareholders.
• Employees: While not directly impacting general employees, the compensation structure for directors can reflect the company's overall approach to equity incentives.

Next Steps

• Monitoring the vesting of the options and Mr. Manke's continued service with OnKure Therapeutics.
• Observing future Form 4 filings for further insider transactions by Mr. Manke or other insiders.

Key Dates

Recommendation

Keywords

OnKure Therapeutics, OKUR, Form 4, SEC filing, stock options, insider transaction, beneficial ownership, director compensation, equity compensation